This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Carmine DeNardo VP and General Manager, SpecialtyPharmacy Services, Omnicell Despite the widespread adoption of electronic health records, pharmacy management systems, and other digital technologies, managing patients and medications across the continuum of care remains a significant challenge.
Sarah Kester, PharmD Pharmaceutical Program Manager, OmnicellSpecialtyPharmacy Services Medication non-adherence is a crippling problem in healthcare today, causing unnecessary hospitalizations and escalating costs. 2 Specialtypharmacy is a hotbed for adherence issues.
As healthcare navigates new and growing challenges post COVID-19 – including labor challenges, supply chain challenges, and disconnected systems – pharmacy leaders need innovative solutions that deliver optimized business and clinical outcomes for medication management. And Omnicell is more than a vendor.
Ngo EVP, Marketing, Strategy & Business Development, Omnicell For more than 25 years, the 340B Drug Pricing Program has provided financial assistance to hospitals and other healthcare facilities serving vulnerable communities to manage rising prescription drug costs.
Court of Appeals for the Third Circuit decided that three drug companies – AstraZeneca, Novo Nordisk, and Sanofi – did not violate federal law when they imposed restrictions, conditions, and other limitations on 340B discount pricing on drugs dispensed at community and specialtypharmacies.
Kristen Dowd Director, Pharmacy Management Services, Omnicell If the 2022 NASP (National Association of SpecialtyPharmacy) Annual Meeting and Expo is any indication, we are approaching a time when specialtypharmacy simply becomes pharmacy – when complex, high-touch biologics become nearly as ubiquitous as their broad-spectrum counterparts.
During an Omnicell-hosted View from Capitol Hill Luncheon and Panel Discussion , Cathy White, 340B Pharmacy Financial Analyst at Cone Health, explained how manufacturer restrictions have impacted her organization. Omnicell can be a valued partner in this effort.
They have placed various restrictions on access to 340B discounts in the retail and specialtypharmacy setting. However, it has been stymied by federal district courts that have issued mixed decisions on the legality of the contract pharmacy program. In its recent budget request to Congress, HRSA also calls on lawmakers to act.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content